Skip to content

Evaluating the outcomes of the polyherbal intervention in the symptoms of Diarrhoea dominant Irritable Bowel Syndrome

A clinical study to evaluate the therapeutic efficacy of Safuf Zarishk in the management of Ishal Dimaghi (Diarrhoea dominant Irritable Bowel Syndrome) - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/083357
Enrollment
60
Registered
2025-03-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K580- Irritable bowel syndrome with diarrhea

Interventions

Intervention1: Safuf ( Powder): It is a polyherbal preparation containing six herbal ingredients. These include Suma q (Rhus coriaria L.), Sounth (Zingiber officinale Rosc.), Ajwain (Trachysper

Sponsors

Central Council for Research In Unani Medicine(CCRUM) New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as the cases of IBS-D as per the ROME IV criteria . 2. History of chronic recurrent symptoms and patient doesn t have adequate relief of the global IBS symptoms at the time of screening. 3. Normal screening tests

Exclusion criteria

Exclusion criteria: 1 Deranged screening tests. 2 Acute onset of symptoms. 3 History of bleeding PR. 4 Nocturnal diarrhoea. 5 Weight loss associated with diarrhoea. 6 Known cases of colon carcinoma, celiac disease, lactose intolerance and inflammatory bowel disease or any other organic disease of the GI system. 7 Constipation dominant IBS. 8 Patients who had taken any type of medications for the relief of diarrhoea and other symptoms at the time of screening including any kind of probiotic, antibiotic or opioids. 9 Pregnancy and lactation, females planning for the pregnancy. 10 Uncontrolled hypertension and Diabetes. 11 Hepatic or kidney diseases

Design outcomes

Primary

MeasureTime frame
1. Change in stool frequency. 2. Change in the stool consistency. 3. Change in stool urgency. 4. Improvement in abdominal pain Timepoint: 30 days

Secondary

MeasureTime frame
1. Overall satisfaction with the treatment and improvement in associated symptoms like bloating and discomfort ( IBSS-S and Birmingham IBS system questionnaire) 2. Safety outcomes of the test drug ( through biochemical evaluation )Timepoint: 30 days

Countries

India

Contacts

Public ContactTooba Bilal Wani

Regional Research Institute of Unani Medicine (RRIUM ), Srinagar

shameem.rather.sr@gmail.com7889584083

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026